S-1: Tenon Medical Files for Resale of 5,673,550 Common Shares Following Warrant Exercises

Tenon Medical is registering for the resale of up to 5,673,550 shares of common stock by a selling stockholder, stemming from the exercise of various series of warrants.

Summary

• Tenon Medical, Inc. has filed a registration statement for the resale of up to 5,673,550 shares of its common stock.
• These shares are issuable upon the exercise of Series C-1, Series C-2, Series D, and Series E warrants previously purchased by a selling stockholder in private placement transactions.
• The company will not receive any proceeds from the resale of these shares by the selling stockholder, but will receive proceeds from any cash exercise of the warrants.
• The warrants have exercise prices of $1.25 and $2.00 per share, with varying expiration dates.
• Tenon Medical intends to use any proceeds from the cash exercise of the warrants for working capital purposes.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol TNON, with a last reported sale price of $1.69 per share on April 1, 2025.
• The selling stockholder, Armistice Capital, LLC, may be deemed an underwriter and may sell shares through public or private transactions.
• Tenon Medical will bear the expenses related to the registration of these shares.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focusing on the details of the share resale registration. While the potential for warrant exercises to provide working capital is a positive, the risk of dilution and market volatility tempers the overall sentiment.

Positives

• The potential exercise of warrants could provide Tenon Medical with additional working capital.
• Registration of the resale shares fulfills contractual obligations to the selling stockholder.
• The company has agreed to bear all expenses in connection with the registration of the Selling Stockholder Shares pursuant to this prospectus.

Negatives

• The resale of a large number of shares could potentially dilute existing shareholders and put downward pressure on the stock price.
• The company will not receive any proceeds from the sale of Selling Stockholder Shares that may be sold from time to time pursuant to this prospectus.

Risks

• An active trading market for the company's shares may not be sustained.
• Future sales of substantial amounts of the company's common stock could adversely affect the market price.
• Purchasers of the company's common stock may incur immediate dilution.
• The company's Series A Preferred Stock and Series B Preferred Stock rank senior to its common stock.
• Conversion of Series A Preferred Stock, the Series B Preferred Stock or the exercise of the Tradeable Warrants, Note Warrants, the Series A Warrants, the Series B Warrants or the Warrants may cause significant dilution to the company's stockholders.
• The company may not be able to cure a Nasdaq listing deficiency if its stock price falls below $0.32 per share.

Future Outlook

Tenon Medical intends to use the proceeds from any cash exercise of the warrants for working capital and general corporate purposes. The company anticipates completing enrollment for its post-market clinical studies of The Catamaran System by the end of the fourth quarter of 2025.

Industry Context

Tenon Medical is focused on addressing the SI-Joint, which it believes is the last major joint to be successfully addressed by the spine implant industry. The company's Catamaran System offers a less invasive approach to SI Joint fusion compared to traditional methods.

Comparison to Industry Standards

• The document mentions that the penetration of a surgical solution for SI-Joint pain has been relatively low (5-7%) due to complex surgical approaches and suboptimal implant design of existing options.
• Tenon's focus is on optimizing the surgical solution to increase market penetration.
• The document compares the disability resulting from SI-Joint disease to other spine conditions like knee and hip arthritis and degenerative disc disease, each of which has multi-billion-dollar surgical implant markets.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and the shares are resold.
• The company's ability to fund operations could be positively impacted by the exercise of warrants.
• The selling stockholder has the opportunity to realize gains from the sale of the shares.

Next Steps

• The selling stockholder may offer and sell the shares from time to time.
• Tenon Medical will monitor the exercise of warrants and utilize any proceeds for working capital.
• Tenon Medical will continue to work towards completing enrollment for its post-market clinical studies of The Catamaran System by the end of the fourth quarter of 2025.

Key Dates

Keywords

resale, common stock, warrants, Tenon Medical, registration statement, Armistice Capital, private placement, TNON, dilution, offering